Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638006 | 0.89 | CXCR4 (0.60) | CXCR4MEN1KMT2ALTA4HPPARG | |
| SCHEMBL2201359 | 0.85 | CXCR4 (0.47) | CXCR4MEN1KMT2AMLLT1 | |
| SCHEMBL2189962 | 0.83 | CXCR4 (0.73) | CXCR4MEN1KMT2ALTA4HPPARG | |
| SCHEMBL1637225 | 0.83 | CXCR4 (0.62) | CXCR4MEN1KMT2ALTA4HFPR2 | |
| SCHEMBL1637333 | 0.82 | CXCR4 (0.61) | CXCR4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12426515 | 0.81 | CXCR4 (0.59) | CXCR4LTA4HSMN1; SMN2PPARGPPARA | |
| SCHEMBL2201355 | 0.79 | KMT2A (0.45) | CXCR4MEN1KMT2A | |
| SCHEMBL12426447 | 0.78 | CXCR4 (0.41) | CXCR4LTA4HPPARGPPARA | |
| SCHEMBL1638428 | 0.78 | DRD4 (0.52) | CXCR4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1638752 | 0.78 | CXCR4 (0.55) | CXCR4MEN1KMT2AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | CXCR4 2546/4885MEN1 1672/4885KMT2A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.